These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 34221371)

  • 1. Effects of canagliflozin on serum potassium in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program.
    Weir MR; Slee A; Sun T; Balis D; Oh R; de Zeeuw D; Perkovic V
    Clin Kidney J; 2021 May; 14(5):1396-1402. PubMed ID: 34221371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials.
    Perkovic V; de Zeeuw D; Mahaffey KW; Fulcher G; Erondu N; Shaw W; Barrett TD; Weidner-Wells M; Deng H; Matthews DR; Neal B
    Lancet Diabetes Endocrinol; 2018 Sep; 6(9):691-704. PubMed ID: 29937267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The sodium-glucose cotransporter-2 inhibitor canagliflozin does not increase risk of non-genital skin and soft tissue infections in people with type 2 diabetes mellitus: A pooled post hoc analysis from the CANVAS Program and CREDENCE randomized double-blind trials.
    Kang A; Smyth B; Neuen BL; Heerspink HJL; Di Tanna GL; Zhang H; Arnott C; Hockham C; Agarwal R; Bakris G; Charytan DM; de Zeeuw D; Greene T; Levin A; Pollock C; Wheeler DC; Mahaffey KW; Perkovic V; Jardine MJ
    Diabetes Obes Metab; 2023 Aug; 25(8):2151-2162. PubMed ID: 37161691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program.
    Neuen BL; Ohkuma T; Neal B; Matthews DR; de Zeeuw D; Mahaffey KW; Fulcher G; Blais J; Li Q; Jardine MJ; Perkovic V; Wheeler DC
    Am J Kidney Dis; 2021 Jan; 77(1):23-34.e1. PubMed ID: 32971190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of canagliflozin on major adverse cardiovascular events by baseline estimated glomerular filtration rate: Pooled Hispanic subgroup analyses from the CANVAS Program and CREDENCE trial.
    Weir MR; Gogate J; Damaraju CV; Correa-Rotter R; Mahaffey KW
    Diabetes Obes Metab; 2022 Jan; 24(1):12-20. PubMed ID: 34463423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An overview of the CANVAS Program and CREDENCE trial: The primary outcomes and key clinical implications for those managing patients with type 2 diabetes.
    Chen AX; Fletcher R; Neuen BL; Neal B; Arnott C
    Diabetes Obes Metab; 2024 Jul; ():. PubMed ID: 39036974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR).
    Weir MR; Kline I; Xie J; Edwards R; Usiskin K
    Curr Med Res Opin; 2014 Sep; 30(9):1759-68. PubMed ID: 24786834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS Program.
    Li J; Badve SV; Zhou Z; Rodgers A; Day R; Oh R; Lee M; Perkovic V; de Zeeuw D; Mahaffey KW; Fulcher G; Matthews DR; Neal B
    Lancet Rheumatol; 2019 Dec; 1(4):e220-e228. PubMed ID: 38229378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study).
    Mahaffey KW; Neal B; Perkovic V; de Zeeuw D; Fulcher G; Erondu N; Shaw W; Fabbrini E; Sun T; Li Q; Desai M; Matthews DR;
    Circulation; 2018 Jan; 137(4):323-334. PubMed ID: 29133604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program.
    Zhou Z; Jardine M; Perkovic V; Matthews DR; Mahaffey KW; de Zeeuw D; Fulcher G; Desai M; Oh R; Simpson R; Watts NB; Neal B
    Diabetologia; 2019 Oct; 62(10):1854-1867. PubMed ID: 31399845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials.
    Neuen BL; Oshima M; Agarwal R; Arnott C; Cherney DZ; Edwards R; Langkilde AM; Mahaffey KW; McGuire DK; Neal B; Perkovic V; Pong A; Sabatine MS; Raz I; Toyama T; Wanner C; Wheeler DC; Wiviott SD; Zinman B; Heerspink HJL
    Circulation; 2022 May; 145(19):1460-1470. PubMed ID: 35394821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function.
    Neuen BL; Ohkuma T; Neal B; Matthews DR; de Zeeuw D; Mahaffey KW; Fulcher G; Desai M; Li Q; Deng H; Rosenthal N; Jardine MJ; Bakris G; Perkovic V
    Circulation; 2018 Oct; 138(15):1537-1550. PubMed ID: 29941478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Canagliflozin on Renal and Cardiovascular Outcomes across Different Levels of Albuminuria: Data from the CANVAS Program.
    Neuen BL; Ohkuma T; Neal B; Matthews DR; de Zeeuw D; Mahaffey KW; Fulcher G; Li Q; Jardine M; Oh R; Heerspink HL; Perkovic V
    J Am Soc Nephrol; 2019 Nov; 30(11):2229-2242. PubMed ID: 31530577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of combination canagliflozin and glucagon-like peptide-1 receptor agonist therapy on intermediate markers of cardiovascular risk in the CANVAS program.
    Arnott C; Neuen BL; Heerspink HJL; Figtree GA; Kosiborod M; Lam CS; Cannon CP; Rosenthal N; Shaw W; Mahaffey KW; Jardine MJ; Perkovic V; Neal B
    Int J Cardiol; 2020 Nov; 318():126-129. PubMed ID: 32569700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS Program.
    Yu J; Arnott C; Neuen BL; Heersprink HL; Mahaffey KW; Cannon CP; Khan SS; Baldridge AS; Shah SJ; Huang Y; Li C; Figtree GA; Perkovic V; Jardine MJ; Neal B; Huffman MD
    ESC Heart Fail; 2021 Apr; 8(2):1482-1493. PubMed ID: 33595905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kidney protection with canagliflozin: A combined analysis of the randomized CANVAS program and CREDENCE trials.
    Sridhar VS; Neuen BL; Fletcher RA; Slee A; Ang FG; Rapattoni W; Arnott C; Cherney DZ; Perkovic V; Wheeler DC; Levin A
    Diabetes Obes Metab; 2023 Aug; 25(8):2331-2339. PubMed ID: 37184050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus.
    Watts NB; Bilezikian JP; Usiskin K; Edwards R; Desai M; Law G; Meininger G
    J Clin Endocrinol Metab; 2016 Jan; 101(1):157-66. PubMed ID: 26580237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different eGFR Decline Thresholds and Renal Effects of Canagliflozin: Data from the CANVAS Program.
    Oshima M; Neal B; Toyama T; Ohkuma T; Li Q; de Zeeuw D; Heerspink HJL; Mahaffey KW; Fulcher G; Canovatchel W; Matthews DR; Perkovic V
    J Am Soc Nephrol; 2020 Oct; 31(10):2446-2456. PubMed ID: 32694216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of canagliflozin in type 2 diabetes in subgroups defined by population-specific body mass index: Insights from the CANVAS Program and CREDENCE trial.
    Yu J; Sweeting AN; Gianacas C; Houston L; Lee V; Fletcher RA; Perkovic V; Li Q; Neuen BL; Berwanger O; Heerspink HJL; de Zeeuw D; Arnott C
    Diabetes Obes Metab; 2023 Dec; 25(12):3724-3735. PubMed ID: 37671609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trial.
    Neal B; Perkovic V; Matthews DR; Mahaffey KW; Fulcher G; Meininger G; Erondu N; Desai M; Shaw W; Vercruysse F; Yee J; Deng H; de Zeeuw D;
    Diabetes Obes Metab; 2017 Mar; 19(3):387-393. PubMed ID: 28120497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.